The solute carrier organic anion transporter 1B1 (SLCO1B1) gene encodes for a membrane-bound sodium-independent organic anion transporter protein (OATP1B1). OATP1B1 plays an important role in mediating hepatic clearance of compounds, most notably, statins, as they are widely prescribed for cholesterol reduction.1 The most common statin-related adverse drug reaction (ADR) is skeletal muscle toxicity, including myopathy, myalgias, and rhabdomyolysis. Low function variants are associated with elevated circulating concentration of statins, resulting in ADR through prolonged systematic statin exposure.2 The evidence linking simvastatin-induced myopathy to rs4149056 in SLCO1B1 has been reproduced in randomized trials and clinical practice-based cohorts. Clinical Pharmacogenetics Implementation Consortium (CPIC) provides dosing and treatment recommendations for patients with reduced SLCO1B1 phenotypes based on the genotyping results.3
Click here for the full CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.